Aptevo closes $4.5 million warrant inducement and PIPE financing

Aptevo Therapeutics Inc. (NASDAQ:APVO) confirmed that its previously announced warrant inducement and private placement transactions closed on August 13, 2026. The transactions closed on August 13, 2026.¹

On August 12, 2026, Aptevo entered into Warrant Inducement and Reload Letters with holders of its existing common stock purchase warrants, issued June 20, 2025, April 3, 2025, and December 12, 2024, under which holders agreed to exercise in full for cash warrants to purchase up to 254,922 shares of common stock at a reduced exercise price of $4.03 per share.¹ That exercise, if completed in full, would give the company gross proceeds of up to approximately $1.0 million before fees.¹

In exchange, the company issued new unregistered inducement warrants to purchase up to 1,274,610 shares of common stock at $4.03 per share.¹ These warrants become exercisable once stockholder approval is obtained and expire on the five year anniversary of that approval.¹

Separately, on the same date, Aptevo entered a Securities Purchase Agreement to sell up to 861,708 unregistered shares at $4.03 per share, or pre-funded warrants in lieu of shares for purchasers electing 4.99% or 9.99% ownership limits, together with common warrants to purchase up to 4,308,540 shares at $4.03 per share.¹

Total gross proceeds from all the transactions were approximately $4.5 million before placement agent fees and expenses.¹ Roth Capital Partners acted as exclusive placement agent and will receive a fee equal to 7% of gross proceeds.¹ Aptevo also agreed to reimburse Roth up to $100,000 in accountable legal expenses.¹

Under a related registration rights agreement, Aptevo must file a resale registration statement by August 22, 2026, and use commercially reasonable efforts to have it declared effective by September 26, 2026, or by October 26, 2026 if the SEC conducts a full review.¹ The company said it expects to use net proceeds for working capital and general corporate purposes.¹